Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$133.34 USD

133.34
1,015,004

+0.26 (0.20%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $133.39 +0.05 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)

by Zacks Equity Research

Sarepta Therapeutics (SRPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak

by Zacks Equity Research

Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations. Stock falls during after-market trading.

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

What Makes Sarepta Therapeutics (SRPT) a New Buy Stock

by Zacks Equity Research

Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics

by Zacks Equity Research

Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics have been highlighted in this Industry Outlook article.

Ekta Bagri headshot

5 Biotech Stocks to Bet On Bright Industry Prospects

by Ekta Bagri

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.

Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

What Makes Sarepta Therapeutics (SRPT) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD

by Zacks Equity Research

Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.

Best Momentum Stocks to Buy for July 3rd

by Zacks Equity Research

SRPT and ASYS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 3, 2024.

New Strong Buy Stocks for July 3rd

by Zacks Equity Research

MONDY, MWA, SRPT, ASYS and CLCO have been added to the Zacks Rank #1 (Strong Buy) List on July 3, 2024.

Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates

by Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.

Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod

by Zacks Equity Research

Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.

Company News for Jun 24, 2024

by Zacks Equity Research

Companies In The News Are: FDS, SRPT, HTZ, ASAN.

Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

by Zacks Equity Research

Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.

Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal

by Zacks Equity Research

Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.

Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Implied Volatility Surging for Sarepta (SRPT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Sarepta (SRPT) stock based on the movements in the options market lately.

Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies

by Zacks Equity Research

Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 763.64% and 10.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?

by Zacks Equity Research

On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.

Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.